Related Tags >> Velcade Takeda Phase III Amgen

Millennium Pharmaceuticals News

Most Popular Millennium Pharmaceuticals Story

Yasuchika Hasegawa - The 25 most influential people in biopharma today

February 7, 2012 — 4:46pm ET | By Suzanne Elvidge

Revising the portfolio Yasuchika HasegawaCEOTakeda Pharmaceutical Yasuchika Hasegawa, CEO of Takeda Pharmaceutical, is a man with ambition. He has moved the Japanese pharmaceutical company into the Read more...

Millennium Pharmaceuticals Press Releases

FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Moderate Growth in the Crohn’s Disease Drug Market Will Mask Dramatic Changes as Sales of Newer and Emerging Agents Will O
Acetylon Announces Publication of Preclinical Pharmacokinetic, Pharmacodynamic and Bone Disease Results for ACY-1215 in Mu
Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
Selecta Biosciences Appoints Takashi Kei Kishimoto, Ph.D., as Chief Scientific Officer

Latest Headlines

Yasuchika Hasegawa - The 25 most influential people in biopharma today
February 7, 2012
SGN-35 - 10 promising late-stage cancer drugs
April 4, 2011
Takeda, Amgen face a setback as lung cancer drug flunks Ph3
March 30, 2011
Takeda looks to Deborah Dunsire to guide oncology work
March 18, 2011
Millennium expands cancer pact with red-hot Seattle Genetics
March 15, 2011
Seattle Genetics' antibody-chemo cancer combo clears pivotal hurdle
September 27, 2010
FDA wants more data on AZ's motavizumab
August 30, 2010
Millennium strikes $365M deal for Seattle Genetics' cancer antibody
December 15, 2009
Despite layoffs, scientists in high demand
September 26, 2008
Takeda gains RNAi tech with $1B Alnylam deal
May 27, 2008
Millennium's Levin uses golden touch to fund start-up
April 29, 2008
Mass. biotechs ripe for buyouts
April 25, 2008
ALSO NOTED: AIDS vaccine researchers years away from success; Amgen reports earnings; and much more...
April 25, 2008
Takeda makes $8.8B bid for Millennium
April 10, 2008
Takeda makes $8.8B bid for Millennium
April 10, 2008
Millennium chief scientist takes offbeat approach
April 3, 2008
ALSO NOTED: Genentech options Exelixis inhibitor; Millennium reports positive data for cancer cocktail; Immtech CEO takes a pay
March 14, 2008
Millennium spent $1.3M on lobbying
February 8, 2008
ALSO NOTED: University spins off drug delivery company; Millennium Phase II meets goal; Will the FDA get money to flex muscles?
November 7, 2007
SPOTLIGHT: Positive Velcade data fuels stock rise
September 18, 2007

Paid Research Reports

More Research Reports >>

Free Newsletter

Most Popular Stories

Webinars

Hottest Products

Featured Jobs

Events